Compare TPVG & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | CCCC |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 185.1M |
| IPO Year | 2013 | 2020 |
| Metric | TPVG | CCCC |
|---|---|---|
| Price | $5.23 | $2.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.90 | ★ $12.20 |
| AVG Volume (30 Days) | 430.7K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.92 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $4.48 | $1.21 |
| 52 Week High | $7.53 | $3.82 |
| Indicator | TPVG | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 51.37 |
| Support Level | $5.03 | $2.30 |
| Resistance Level | $5.39 | $2.89 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 38.31 | 50.00 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.